Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17271387 | 1.00 | MAPT (0.34) | MAPTALDH1A1HCRTR1HCRTR2POLB | |
| SCHEMBL16994522 | 1.00 | MAPT (0.34) | MAPTALDH1A1HCRTR1HCRTR2POLB | |
| SCHEMBL9901579 | 0.92 | USP30 (0.38) | MAPTHCRTR1HCRTR2POLBMEN1 | |
| SCHEMBL16994488 | 0.92 | USP30 (0.38) | MAPTHCRTR1HCRTR2POLBMEN1 | |
| SCHEMBL16994490 | 0.85 | GRM4 (0.32) | — | |
| SCHEMBL17271383 | 0.85 | GRM4 (0.32) | — | |
| SCHEMBL17271382 | 0.85 | GRM4 (0.32) | — | |
| SCHEMBL16994506 | 0.84 | QPCT (0.37) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9901650 | 0.84 | QPCT (0.37) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9901652 | 0.84 | QPCT (0.37) | MAPTALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2017-04-20 | — | — | US | claimed |
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| EP-2649048-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | Radikal Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012077108-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOS1 | MAPT 2036/4885ALDH1A1 1794/4885HCRTR1 4049/4885 |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | MAPT 2271/4885ALDH1A1 1804/4885HCRTR1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.